Results 91 to 100 of about 19,899 (238)

Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.

PLoS ONE, 2012
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of autosomal dominant familial Parkinson's disease (PD). LRRK2 encodes a multi-domain protein containing GTPase and kinase enzymatic domains.
Alzbeta Trancikova, Adamantios Mamais, Philip J Webber, Klodjan Stafa, Elpida Tsika, Liliane Glauser, Andrew B West, Rina Bandopadhyay, Darren J Moore   +8 more
doaj   +1 more source

Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge.
Elena Ojeda‐Lepe, Sergio García‐Díaz, Laura Muñoz‐Delgado, Miguel Martín‐Bórnez, Silvia Jesús, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Rafael Díaz‐Belloso, Daniel Macías‐García, Astrid Adarmes‐Gómez, Antonio Luque‐Ambrosiani, Rocío Pineda‐Sánchez, Lorena Clavijo‐Jiménez, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +15 more
wiley   +1 more source

LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner

Cell Death and Disease, 2023
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson’s disease (PD), with growing importance also for Crohn’s disease and cancer.
Elżbieta Kania, Jaclyn S. Long, David G. McEwan, Kirsten Welkenhuyzen, Rita La Rovere, Tomas Luyten, John Halpin, Evy Lobbestael, Veerle Baekelandt, Geert Bultynck, Kevin M. Ryan, Jan B. Parys   +11 more
doaj   +1 more source

Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM

Cell Discovery
LRRK2 is one of the most promising drug targets for Parkinson’s disease. Though type I kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors are being actively pursued due to the potential undesired effects ...
Hanwen Zhu, Patricia Hixson, Wen Ma, Ji Sun   +3 more
doaj   +1 more source

Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene Review.

, 2018
peer reviewedThis comprehensive MDSGene review is devoted to the three autosomal-dominant PD forms: PARK-SNCA, PARK-LRRK2, and PARK-VPS35. It follows MDSGene's standardized data extraction protocol, screened a total of 2,972 citations, and is based on ...
Inke R. König, Lohmann, Katja, Petkovic, Sonja, Kasten, Meike, Susen Schaake, Trinh, Joanne, Harutyun Madoev, Katja Lohmann, Christina M. Lill, Lill, Christina M., GRÜNEWALD, Anne, Schaake, Susen, Anne Grünewald, Klein, Christine, Connie Marras, Jana Huang, König, Inke R., Florentine M.J. Zeldenrust, Shahad Almuammar, Huang, Jana, Zeldenrust, Florentine M. J., Joanne Trinh, Madoev, Harutyun, Sonja Petkovic, Christine Klein, Meike Kasten, Almuammar, Shahad, Marras, Connie   +27 more
core   +1 more source

Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2

eLife
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Mutations in human leucine-rich repeat kinase 2 (LRRK2), a multi-domain protein containing both a kinase and a GTPase, are a leading cause of the familial form of PD ...
Siyu Chen, Tamar Basiashvili, Joshua Hutchings, Marta Sanz Murillo, Amalia Villagran Suarez, Erica Xiong, Jaime Alegrio Louro, Andres E Leschziner, Elizabeth Villa   +8 more
doaj   +1 more source

LRRK2 in Parkinson's disease and dementia with Lewy bodies

Molecular Neurodegeneration, 2006
Background Mutations in LRRK2 encoding leucine-rich repeat kinase 2 are thus far the most frequent genetic cause associated with autosomal dominant and idiopathic Parkinson's disease (PD).
Zhu Xiongwei, Babar Asim, Siedlak Sandra L, Yang Qiwei, Ito Genta, Iwatsubo Takeshi, Smith Mark A, Perry George, Chen Shu G   +8 more
doaj   +1 more source

The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System

Frontiers in Neuroscience, 2020
The leucine-rich repeat kinase 2 (LRRK2), the most common causative gene for autosomal-dominant familial Parkinson’s disease, encodes a large protein kinase harboring multiple characteristic domains.
Tomoki Kuwahara, Takeshi Iwatsubo
doaj   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source

Cellular effects of LRRK2 mutations [PDF]

Biochemical Society Transactions, 2012
Mutations in LRRK2 (leucine-rich repeat kinase 2) are a relatively common cause of inherited PD (Parkinson's disease), but the mechanism(s) by which mutations lead to disease are poorly understood. In the present paper, I discuss what is known about LRRK2 in cellular models, focusing specifically on assays that have been used to tease apart the effects
openaire   +2 more sources